Regulated information
June 1, 2020
Breda, the Netherlands / Ghent,
Belgium — argenx (Euronext & Nasdaq: ARGX), a
clinical-stage biotechnology company developing a deep pipeline of
differentiated antibody-based therapies for the treatment of severe
autoimmune diseases and cancer, announced today the closing of its
previously announced global offering of an aggregate of 4,207,292
ordinary shares (including ordinary shares represented by American
Depositary Shares (ADSs)), which includes the full exercise of the
underwriters’ option to purchase 548,777 additional ADSs. The gross
proceeds from the global offering were approximately $862.5 million
(approximately €784.7 million).
J.P. Morgan, Cowen and BofA Securities acted as
joint bookrunning managers for the offering. Stifel, JMP
Securities, Wedbush PacGrow, Nomura and Kempen & Co acted as
co-managers for the offering.
The securities were offered in the United States
pursuant to an automatically effective shelf registration statement
that was previously filed with the Securities and Exchange
Commission (SEC). A preliminary prospectus supplement relating to
the securities was filed with the SEC on May 26, 2020 and a final
prospectus supplement relating to the securities was filed with the
SEC on May 29, 2020 and are available on the SEC’s website at
www.sec.gov. Copies of the final prospectus supplement and the
accompanying prospectus relating to the U.S. offering may be
obtained for free from J.P. Morgan Securities LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
or by telephone at (866) 803-9204, or by email at
prospectus-eq_fi@jpmchase.com; from Cowen and Company, LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, Attn: Prospectus Department, by email at
PostSaleManualRequests@broadridge.com, or by telephone at (833)
297-2926; or from BofA Securities, NC1-004-03-43, 200 North College
Street, 3rd floor, Charlotte, North Carolina 28255-0001, Attn:
Prospectus Department, or by email at
dg.prospectus_requests@bofa.com.
In addition, argenx announces the listing of and
the commencement of dealings in its 4,207,292 new ordinary shares
on the regulated market of Euronext Brussels. The listing occurs
pursuant to a listing prospectus approved by the Dutch regulator
(“Stichting Autoriteit Financiële Markten”) (the “AFM”) and
passported to Belgium in accordance with article 25 of Regulation
(EU) 2017/1129 of the European Parliament and of the Council of 14
June 2017 on the prospectus to be published when securities are
offered to the public or admitted to trading on a regulated market,
and repealing Directive 2003/71/EC (as amended, the “Prospectus
Regulation”). The listing prospectus, together with a Dutch
translation of the summary, is available on the website of argenx
(www.argenx.com) and copies may be obtained for free from argenx
upon request at info@argenx.com or by telephone at (32) 9 310 34 19
.
This press release is for information purposes
only and does not constitute, and should not be construed as, an
offer to sell or the solicitation of an offer to buy or subscribe
to any securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale is not
permitted or to any person or entity to whom it is unlawful to make
such offer, solicitation or sale. Reference is also made to the
restrictions set out in “Important information” below. This press
release is not for publication or distribution, directly or
indirectly, in or into any state or jurisdiction into which doing
so would be unlawful or where a prior registration or approval is
required for such purpose.
About argenx
argenx is a global immunology company developing
antibody-based medicines for patients suffering from severe
autoimmune diseases and cancer. By translating immunology
breakthroughs into innovative drug candidates, argenx is building a
world-class portfolio of first-in-class antibodies in both early
and late clinical-stages of development. argenx is evaluating
efgartigimod in multiple serious autoimmune indications and
cusatuzumab in hematological malignancies in collaboration with
Janssen, along with advancing earlier stage assets within its
therapeutic franchises.
For further information, please
contact:Beth DelGiacco, Vice President, Investor
Relations (US)+1 518 424 4980bdelgiacco@argenx.com
Joke Comijn, Director Corporate
Communications & Investor Relations (EU)+32 (0)477 77 29
44+32 (0)9 310 34 19jcomijn@argenx.com
Important information
The preliminary prospectus supplement and final
prospectus supplement in respect of the U.S. offering do not
constitute a prospectus within the meaning of the Prospectus
Regulation and has not been approved by the AFM or the Belgian
Financial Services and Markets Authority (Autoriteit Financiële
Diensten en Markten) or any other European Supervisory
Authority.
No public offering will be made and no one has
taken any action that would, or is intended to, permit a public
offering in any country or jurisdiction, other than the United
States, where any such action is required, including in the
European Economic Area. In the European Economic Area, the offering
to which this press release relates will only be available to, and
will be engaged in only with, qualified investors within the
meaning of the Prospectus Regulation.
European Economic Area:
No action has been or will be taken to offer the
ordinary shares to a retail investor established in the European
Economic Area as part of the global offering. For the purposes of
this paragraph:
a. The expression
“retail investor” means
a person who is one (or more) of:
i. |
|
a retail client as defined in point (11) of
Article 4(1) of Directive 2014/65/EU (as amended,
“MiFID II”); or |
ii. |
|
a customer within the meaning of Directive 2016/97/EU, as amended,
where that customer would not qualify as a professional client as
defined in point (10) of Article 4(1) of MiFID II;
or |
iii. |
|
not a “qualified investor” as defined in the Prospectus Regulation;
and |
b. the expression
“offer” means any communication in any form and by
any means of sufficient information on the terms of the offer and
securities to be offered so as to enable an investor to decide to
purchase or subscribe these securities.
In addition, in the United Kingdom, the
transaction to which this press release relates will only be
available to, and will be engaged in only with, investment
professionals falling within Article 19(5) of the
Financial Services and Markets Act (Financial Promotion) Order
2005, as amended (the Order), persons falling within
Article 49(2)(a) to (d) of the Order, and other
persons to whom this announcement may lawfully be communicated (all
such persons together being referred to as “relevant persons”). The
securities referred to herein are only available to, and any
invitation, offer or agreement to subscribe, purchase or otherwise
acquire such securities will be engaged in only with relevant
persons. Any person who is not a relevant person should not act or
rely on this communication or any of its contents.
This press release is not an approved prospectus
by the Financial Services Authority or by any other regulatory
authority in the United Kingdom within the meaning of
Section 85 of the Order.
Argen X (EU:ARGX)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Argen X (EU:ARGX)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024